Condition: Multiple Myeloma (MM) · Sponsor: C4 Therapeutics, Inc.
The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity. Cemsidomide will be taken orally each cycle for 14 days on/14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.
This description comes directly from the study's public registry record.
Study Medical Officer · (617) 231-0700 · clinicaltrials@c4therapeutics.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Not Yet Recruiting |
| UC Davis Comprehensive Cancer Center | Sacramento, California, United States | Not Yet Recruiting |
| UCLA Health, Jonsson Comprehensive Cancer Center | Santa Monica, California, United States | Not Yet Recruiting |
| University of Florida | Gainesville, Florida, United States | Not Yet Recruiting |
| University of Miami | Miami, Florida, United States | Not Yet Recruiting |
| Winship Cancer Institute, Emory University | Atlanta, Georgia, United States | Recruiting |
| Loyola University Medical Center | Maywood, Illinois, United States | Not Yet Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Not Yet Recruiting |
| Norton Cancer Institute St. Matthews | Louisville, Kentucky, United States | Not Yet Recruiting |
| University of Maryland Greenbaum Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| University of Nebraska | Omaha, Nebraska, United States | Not Yet Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07280013